APS.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 22:59):

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States...

Stats
Dzisiejszy wolumen	34 400.00
Średni wolumen	8 958.00
Kapitalizacja rynkowa	26.72M
EPS	$0 ( 2024-03-26 )
Następna data zysków	( $-1.010 ) 2024-05-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.0260 (1.53%)

Aptose Biosciences Inc Korelacja

10 Najbardziej pozytywne korelacje
IVQ.TO	0.87
ME.TO	0.86
IVX.V	0.86
AH.TO	0.859
PYR.TO	0.859
NBVA.V	0.851
GKO.V	0.851
PLRB.V	0.847
LGD.TO	0.842
GBT.TO	0.838

10 Najbardziej negatywne korelacje
APL.V	-0.878
MAGT.TO	-0.872
SNC.TO	-0.865
URB.TO	-0.862
MCB.TO	-0.86
WE.V	-0.851
HSAV.TO	-0.849
SJR-B.TO	-0.848
HURA.TO	-0.847
DRX.TO	-0.844

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptose Biosciences Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-7.58

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-7.58

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.440

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.